PL EN
Two cases of paroxysmal nocturnal hemoglobinuria: Clinical observations and treatment approaches
 
Więcej
Ukryj
1
Students’ Scientific Club, Department of Pediatric Hematology and Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
 
2
Department of Pediatric Hematology and Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
 
 
Autor do korespondencji
Matylda Kujawińska   

Studenckie Koło Naukowe, Katedra i Klinika Pediatrii, Hematologii i Onkologii Dziecięcej, SPSK Nr 1 im. prof. S. Szyszko ŚUM, ul. 3 Maja 13/15, 41-800 Zabrze
 
 
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder associated with an acquired clonal defect of the hematopoietic stem cell. Abnormal expression of complement inhibitors results in hemolysis and thromboembolic complications. Here we present two pediatric cases of PNH. The first patient died due to progressive and nonspecific thromboembolic complications, particularly affecting the abdominal organs and vessels. Allogeneic bone marrow transplantation from a related donor, liver transplantation, and complement inhibitor therapy were not feasible. In the second patient, treatment with hematopoietic stem cell transplantation from an unrelated donor was successful, although complicated by episodes of graft-versus-host disease (GvHD) and recurrent viral infections. Considering the specific nature of PNH, early diagnosis and careful management of complications during treatment remain essential aspects.
REFERENCJE (22)
1.
Piekarska A, Lewandowski K. Paroxysmal nocturnal hemoglobinuria – current state of knowledge, diagnostics, accessible therapies and future perspectives. Hematol Clin Pract. 2020;11(1):30–44. doi: 10.5603/Hem.2020.0004.
 
2.
Karwacki MW, Adamowicz-Salach A, Matysiak M, Pankiewicz A. Paroxysmal nocturnal hemoglobinuria in children as a perfect example of rare disease hidden behind a mask of different clinical entities. Clinical, ethical and societal dilemma concerning diagnosis of ultrarare disorders based on case presentation. Nowa Pediatr. 2019; 23(1):51–58. doi: 10.25121/NP.2019.23.1.51.
 
3.
Paroxysmal Nocturnal Hemoglobinuria 1; PNH: #300818. Online Mendelian Inheritance in Man [online] https://omim.org/entry/300818 [accessed on 17 September 2025].
 
4.
Szlendak U, Budziszewska B, Spychalska J, Drozd-Sokołowska J, Patkowska E, Nowak J. Paroxysmal nocturnal hemoglobinuria: advances in the understanding of pathophysiology, diagnosis, and treatment. Pol Arch Intern Med. 2022;132(6):16271. doi: 10.20452/pamw.16271.
 
5.
Shoaib E, Imam F, Khan M, Jaber Amin MH. Advancements in PNH treatment: crovalimab’s clinical efficacy. Ann Med Surg (Lond). 2024;86(12):6921–6922. doi: 10.1097/MS9.0000000000002706.
 
6.
Paroxysmal nocturnal hemoglobinuria: ORPHA:447. Orphanet [online] https://www.orpha.net/en/disea... [accessed on 17 September 2025].
 
7.
Kozińska J. A patient with nocturnal paroxysmal hemoglobinuria in everyday medical practice: from a primary care physician to a hematologist - a case report. Med Faktów 2023;16(2(59)):255–260. doi: 10.24292/01.MF.0223.20.
 
8.
Spychalska J, Brojer E. Nocna napadowa hemoglobinuria – patofizjologia, klasyfikacja i nowoczesna diagnostyka. Hematol Clin Pract. 2013;4(4):301–320.
 
9.
Ge M, Shi J, Li X, Shao Y, Huang J, Huang Z, et al. Clinical features and survival of Asian pediatric patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. Acta Haematol. 2015;134(1):1–6. doi: 10.1159/000369773.
 
10.
Wachowiak J, Balwierz W, Chybicka A, Drabko K, Gorczyńska E, Goździk J, et al. Indications for hematopoietic stem cell transplantation in children and adolescents: recommendations of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation in the year 2014. Acta Haematol Pol. 2014;45(4):301–312. doi: 10.1016/j.achaem.2014.09.001.
 
11.
Kamranzadeh Fumani H, Zokaasadi M, Kasaeian A, Alimoghaddam K, Mousavi SA, Bahar B, et al. Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: a retrospective single-center study. Hematol Oncol. 2017;35(4):935–938. doi: 10.1002/hon.2367.
 
12.
Yılmaz F, Soyer N, Cengiz Seval G, Civriz Bozdağ S, Topcuoğlu P, Ünal A, et al. Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia: a multicenter Turkish experience. Turk J Haematol. 2021;38(3):195–203. doi: 10.4274/tjh.galenos.2021.2021.0105.
 
13.
Markiewicz M, Drozd-Sokołowska J, Biecek P, Dzierżak-Mietła M, Boguradzki P, Staniak M, et al. Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: multicenter analysis by the Polish Adult Leukemia Group. Biol Blood Marrow Transplant. 2020;26(10):1833–1839. doi: 10.1016/j.bbmt.2020.05.024.
 
14.
de Latour RP, Risitano A, Dufour C. Severe Aplastic Anemia and PNH. In: Carreras E, Dufour C, Mohty M, Kröger N [eds.]. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham: Springer; 2019, pp. 579–585.
 
15.
Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12(6):682–687. doi: 10.1038/nm1419.
 
16.
Terriou L, Lee JW, Forsyth C, Griffin M, Szer J, Röth A, et al. Long-term effectiveness of eculizumab: Data from the International PNH Registry. Eur J Haematol. 2023;111(5):796–804. doi: 10.1111/ejh.14080.
 
17.
Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL. Hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria in the age of eculizumab. Biol Blood Marrow Transplant. 2019;25(7):1331–1339. doi: 10.1016/j.bbmt.2019.01.033.
 
18.
Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. Eur J Haematol. 2022;109(3):205–214. doi: 10.1111/ejh.13783.
 
19.
Chonat S, Kulagin A, Maschan A, Bartels M, Buechner J, Punzalan R, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024;8(11):2813–2824. doi: 10.1182/bloodadvances.2023012267.
 
20.
Holt M, Kelly R, Hughes S, Munir T, Varghese A, Nagumantry S, et al. First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2025;206(6):1859–1862. doi: 10.1111/bjh.20073.
 
21.
Weitz IC. Pegcetacoplan: A new opportunity for complement inhibition in PNH. J Blood Med. 2023;14:239–245. doi: 10.2147/JBM.S362220.
 
22.
Röth A, Kulasekararaj AG, Scheinberg P, Nishimura JI. Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape. Immunotherapy. 2024;16(20–22):1185–1196. doi: 10.1080/1750743X.2024.2433410.
 
eISSN:1734-025X
Journals System - logo
Scroll to top